Rectal Cancer Clinical Trial
Official title:
Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology
This innovative study will involve the use of probe-based confocal laser endomicroscopy, a
new medical imaging technology never used for surgical indications to date. Virtual biopsies
(pCLE images) will be compared to histopathology analysis.
This study focuses on the evaluation of rectal tumor margins. The hypothesis is that pCLE
will allow identification of rectal tumor margin, comparable to that of histopathology. In
the future, decision of resection margin could rely on intraoperative pCLE exam.
The proposed study is a feasibility study, first in the indication of rectal cancer.
Defining the limits of resection of rectal tumors is often imprecise. The identification of
the banks of a tumor becomes critical when it comes to the decision to potentially sacrifice
the sphincter during the surgical resection. Currently tumor margins are identified by direct
examination by the surgeon, or using flexible endoscopy. Endoscopy and confocal microscopy
could provide precise images of tumor enabling the reliable definition of resection margins.
There would be a direct benefit for the patient, whom sphincter could be preserved. pCLE
(probe-based Confocal Laser Endomicroscopy) has already been widely used for colorectal
lesions, and its value proposition has been demonstrated and validated in several studies.
This study is the first using pCLE intraoperatively. Study results may lead the use of pCLE
to validate surgical procedure decision (resection margin) and to a revision of patient
management for colorectal cancer, by adapting neoadjuvant radiochemotherapy to the patient's
responder status.
The goal is to identify tumor margin (lower pole) to optimize the resection margin, and to
limit resection of healthy rectal tissue for optimal anal sphincter preservation. Moreover,
determining the optimal date of surgery following neoadjuvant radiochemotherapy in rectal
cancer is being discussed and no consensus has been reached. Therefore, to date, there is no
formal evaluation of tumor response. This is partly due to the lack of information on tumor
state and tumor evolution over time, between the end of radiochemotherapy and surgery.
Histological follow up of tumor would provide supporting information to fill this gap.
However, frequent tumor biopsies are not possible. Alternatively, probe-based confocal laser
endomicroscopy (pCLE) could allow for a sequential analysis of tumor response. Response to
treatment could be assessed and used to define optimal date of surgical resection, depending
on patient responding status to treatment. Responding patients would undergo surgery at a
later date than non-responders, in whom surgery could be performed earlier.
Benefits of the study lay in the more accurate definition of resection margins, with its
associated potential therapeutic impact of the anal sphincter preservation and in the
definition of the optimal date of rectal tumor resection, based on response status to
radiochemotherapy.
Study interests are :
- Microscopic structure of tumor will be analyzed at the cellular and microvascular levels
and compared to healthy mucosa.
- Evolution of response during and following radiochemotherapy will be assessed, and will
help classify patients as responders/non responders.
- pCLE results will be compared to histopathology results on pre-treatment and resection
biopsies.
- Images gathered through the imaging modalities (WLE, pCLE, EUS) along with
histopathology results will be combined to create an atlas and database of rectal
tumors.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |